9.90
-0.05 (-0.50%)
| Previous Close | 9.95 |
| Open | 9.99 |
| Volume | 3,386,792 |
| Avg. Volume (3M) | 5,093,623 |
| Market Cap | 3,054,481,920 |
| Price / Earnings (Forward) | 20.83 |
| Price / Sales | 5.03 |
| Price / Book | 13.10 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -5.41% |
| Operating Margin (TTM) | -6.35% |
| Diluted EPS (TTM) | -0.090 |
| Quarterly Revenue Growth (YOY) | 13.40% |
| Total Debt/Equity (MRQ) | 229.11% |
| Current Ratio (MRQ) | 3.34 |
| Operating Cash Flow (TTM) | 3.56 M |
| Levered Free Cash Flow (TTM) | 29.27 M |
| Return on Assets (TTM) | 3.95% |
| Return on Equity (TTM) | -18.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Amicus Therapeutics, Inc. | Bearish | Mixed |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.00 |
|
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.72% |
| % Held by Institutions | 103.25% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Perceptive Advisors Llc | 30 Sep 2025 | 6,370,851 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 19.00 (JP Morgan, 91.92%) | Buy |
| Median | 14.00 (41.41%) | |
| Low | 11.00 (Goldman Sachs, 11.11%) | Hold |
| Average | 14.67 (48.18%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 8.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 06 Nov 2025 | 19.00 (91.92%) | Buy | 8.90 |
| Goldman Sachs | 05 Nov 2025 | 11.00 (11.11%) | Hold | 9.19 |
| Needham | 18 Sep 2025 | 14.00 (41.41%) | Buy | 8.48 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CAMPBELL BRADLEY L | - | 9.80 | -14,587 | -142,953 |
| PROUT SAMANTHA | 9.80 | - | 32,193 | 315,491 |
| ROSENBERG ELLEN | - | 9.95 | -59,621 | -592,002 |
| Aggregate Net Quantity | -42,015 | |||
| Aggregate Net Value ($) | -419,464 | |||
| Aggregate Avg. Buy ($) | 9.80 | |||
| Aggregate Avg. Sell ($) | 9.90 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PROUT SAMANTHA | Officer | 01 Dec 2025 | Acquired (+) | 32,193 | 9.80 | 315,491 |
| CAMPBELL BRADLEY L | Officer | 01 Dec 2025 | Sell (-) | 14,587 | 9.80 | 142,953 |
| CAMPBELL BRADLEY L | Officer | 01 Dec 2025 | Option execute | 14,587 | - | - |
| ROSENBERG ELLEN | Officer | 26 Nov 2025 | Sell (-) | 23,621 | 10.02 | 236,682 |
| ROSENBERG ELLEN | Officer | 26 Nov 2025 | Option execute | 23,621 | - | - |
| ROSENBERG ELLEN | Officer | 25 Nov 2025 | Sell (-) | 36,000 | 9.87 | 355,320 |
| ROSENBERG ELLEN | Officer | 25 Nov 2025 | Option execute | 36,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 04 Nov 2025 | Announcement | Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates |
| 31 Oct 2025 | Announcement | Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 |
| 23 Oct 2025 | Announcement | Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |